##GS140127_01 ref_correl: 0.945 (median: 0.971)
##GS140127_01 cnvs: 174 (median: 43)
##GS140127_01 qc_errors: 
#chr	start	end	sample	size	region_count	region_copy_numbers	region_zscores	region_cnv_af	region_coordinates	overlaps_cnp_region	genes	dosage_sensitive_disease_genes	omim
chr1	6535512	6535592	GS140127_01	81	1	3	4.32	0.046	chr1:6535512-6535592		PLEKHG5		611101_[PLEKHG5_(CONFIRMED)_SPINAL_MUSCULAR_ATROPHY,DISTAL,AUTOSOMAL_RECESSIVE,4,611067|CHARCOT-MARIE-TOOTH_DISEASE,RECESSIVE_INTERMEDIATE_C,615376]
chr1	12066585	12066760	GS140127_01	176	1	1	-3.81	0.026	chr1:12066585-12066760		MFN2		608507_[MFN2_(CONFIRMED)_CHARCOT-MARIE-TOOTH_DISEASE,AXONAL,TYPE_2A2A,609260|HEREDITARY_MOTOR_AND_SENSORY_NEUROPATHY_VIA,601152|CHARCOT-MARIE-TOOTH_DISEASE,AXONAL,TYPE_2A2B,617087]
chr1	22190583	22191576	GS140127_01	994	2	1,1	-2.48,-3.59	0.039,0.026	chr1:22190583-22190716,chr1:22191326-22191576		HSPG2	HSPG2	142461_[HSPG2_(CONFIRMED)_SCHWARTZ-JAMPEL_SYNDROME,TYPE_1,255800|DYSSEGMENTAL_DYSPLASIA,SILVERMAN-HANDMAKER_TYPE,224410]
chr1	24122631	24122765	GS140127_01	135	1	1	-4.23	0.046	chr1:24122631-24122765		GALE		606953_[GALE_(CONFIRMED)_GALACTOSE_EPIMERASE_DEFICIENCY,230350]
chr1	24172554	24172673	GS140127_01	120	1	3	3.68	0.020	chr1:24172554-24172673		FUCA1		612280_[FUCA1_(CONFIRMED)_FUCOSIDOSIS,230000]
chr1	43205502	43205935	GS140127_01	434	1	1	-4.42	0.072	chr1:43205502-43205935		CLDN19		610036_[CLDN19_(CONFIRMED)_HYPOMAGNESEMIA_5,RENAL,WITH_OCULAR_INVOLVEMENT,248190]
chr1	67518444	67518550	GS140127_01	107	1	3	4.03	0.026	chr1:67518444-67518550		SLC35D1		610804_[SLC35D1_(CONFIRMED)_SCHNECKENBECKEN_DYSPLASIA,269250]
chr1	92951561	92951638	GS140127_01	78	1	4	4.71	0.046	chr1:92951561-92951638		GFI1		600871_[GFI1_(CONFIRMED)_NEUTROPENIA,SEVERE_CONGENITAL_2,AUTOSOMAL_DOMINANT,613107|NEUTROPENIA,NONIMMUNE_CHRONIC_IDIOPATHIC,OF_ADULTS,607847]
chr1	109756505	109756760	GS140127_01	256	1	3	4.70	0.065	chr1:109756505-109756760		SARS		
chr1	161136171	161136472	GS140127_01	302	1	3	3.99	0.085	chr1:161136171-161136472		PPOX		600923_[PPOX_(PROVISIONAL)_PORPHYRIA_VARIEGATA,176200]
chr1	161179891	161180189	GS140127_01	299	2	3,3	4.17,2.62	0.026,0.020	chr1:161179891-161179988,chr1:161180084-161180189		NDUFS2		602985_[NDUFS2_(PROVISIONAL)_MITOCHONDRIAL_COMPLEX_I_DEFICIENCY,252010]
chr1	201022327	201023699	GS140127_01	1373	3	1,1,1	-3.00,-3.75,-2.52	0.013,0.013,0.052	chr1:201022327-201022412,chr1:201022577-201022725,chr1:201023623-201023699		CACNA1S		114208_[CACNA1S_(CONFIRMED)_HYPOKALEMIC_PERIODIC_PARALYSIS,TYPE_1,170400|MALIGNANT_HYPERTHERMIA_SUSCEPTIBILITY_5,601887|THYROTOXIC_PERIODIC_PARALYSIS,SUSCEPTIBILITY_TO,1,188580]
chr1	235530718	235530877	GS140127_01	160	1	3	5.08	0.059	chr1:235530718-235530877		TBCE	TBCE	604934_[TBCE_(CONFIRMED)_KENNY-CAFFEY_SYNDROME,TYPE_1,244460|HYPOPARATHYROIDISM-RETARDATION-DYSMORPHISM_SYNDROME,241410|ENCEPHALOPATHY,PROGRESSIVE,WITH_AMYOTROPHY_AND_OPTIC_ATROPHY,617207]
chr1	247579448	247579505	GS140127_01	58	1	4	5.00	0.020	chr1:247579448-247579505		NLRP3		606416_[NLRP3_(CONFIRMED)_FAMILIAL_COLD-INDUCED_INFLAMMATORY_SYNDROME_1,120100|MUCKLE-WELLS_SYNDROME,191900|CINCA_SYNDROME,607115]
chr2	27545305	27545979	GS140127_01	675	2	3,3	3.41,5.13	0.065,0.065	chr2:27545305-27545399,chr2:27545909-27545979		MPV17		137960_[MPV17_(PROVISIONAL)_MITOCHONDRIAL_DNA_DEPLETION_SYNDROME_6_(HEPATOCEREBRAL_TYPE),256810]
chr2	44139561	44139707	GS140127_01	147	1	3	4.12	0.137	chr2:44139561-44139707		LRPPRC		607544_[LRPPRC_(CONFIRMED)_LEIGH_SYNDROME,FRENCH-CANADIAN_TYPE,220111]
chr2	109367710	109368169	GS140127_01	460	2	3,3	4.71,3.86	0.013,0.020	chr2:109367710-109367911,chr2:109367974-109368169		RANBP2		601181_[RANBP2_(PROVISIONAL)_ENCEPHALOPATHY,ACUTE,INFECTION-INDUCED,3,SUSCEPTIBILITY_TO,608033]
chr2	152553141	152553259	GS140127_01	119	1	3	3.83	0.092	chr2:152553141-152553259		NEB		161650_[NEB_(CONFIRMED)_NEMALINE_MYOPATHY_2,AUTOSOMAL_RECESSIVE,256030]
chr2	170151100	170151230	GS140127_01	131	1	3	3.65	0.020	chr2:170151100-170151230		LRP2	LRP2	600073_[LRP2_(CONFIRMED)_DONNAI-BARROW_SYNDROME,222448]
chr2	179558326	179558426	GS140127_01	101	1	3	4.57	0.039	chr2:179558326-179558426		TTN,TTN-AS1		188840_[TTN_(CONFIRMED)_CARDIOMYOPATHY,FAMILIAL_HYPERTROPHIC,9,613765|CARDIOMYOPATHY,DILATED,1G,604145|TIBIAL_MUSCULAR_DYSTROPHY,TARDIVE,600334|MUSCULAR_DYSTROPHY,LIMB-GIRDLE,TYPE_2J,608807|MYOPATHY,PROXIMAL,WITH_EARLY_RESPIRATORY_MUSCLE_INVOLVEMENT,603689|SALIH_MYOPATHY,611705]
chr2	190444529	190444616	GS140127_01	88	1	3	4.70	0.026	chr2:190444529-190444616		SLC40A1		604653_[SLC40A1_(CONFIRMED)_HEMOCHROMATOSIS,TYPE_4,606069]
chr2	191849026	191850396	GS140127_01	1371	2	3,3	2.51,3.60	0.020,0.007	chr2:191849026-191849129,chr2:191850335-191850396		STAT1		600555_[STAT1_(PROVISIONAL)_IMMUNODEFICIENCY_31A,MYCOBACTERIOSIS,AUTOSOMAL_DOMINANT,614892|IMMUNODEFICIENCY_31B,MYCOBACTERIAL_AND_VIRAL_INFECTIONS,AUTOSOMAL_RECESSIVE,613796|IMMUNODEFICIENCY_31C,AUTOSOMAL_DOMINANT,614162]
chr2	198363389	198363584	GS140127_01	196	1	3	3.57	0.046	chr2:198363389-198363584		HSPD1		118190_[HSPD1_(CONFIRMED)_SPASTIC_PARAPLEGIA_13,AUTOSOMAL_DOMINANT,605280|LEUKODYSTROPHY,HYPOMYELINATING,4,612233]
chr2	207024055	207024253	GS140127_01	199	1	3	4.15	0.033	chr2:207024055-207024253		NDUFS1		157655_[NDUFS1_(PROVISIONAL)_MITOCHONDRIAL_COMPLEX_I_DEFICIENCY,252010]
chr2	227898116	227906981	GS140127_01	8866	2	3,3	3.87,3.67	0.105,0.098	chr2:227898116-227898207,chr2:227906854-227906981		COL4A4		120131_[COL4A4_(CONFIRMED)_ALPORT_SYNDROME,AUTOSOMAL_RECESSIVE,203780|HEMATURIA,FAMILIAL_BENIGN]
chr2	240098099	240098269	GS140127_01	171	1	1	-3.70	0.013	chr2:240098099-240098269		HDAC4	HDAC4	
chr3	4508650	4508976	GS140127_01	327	1	1	-3.88	0.033	chr3:4508650-4508976		SUMF1	SUMF1	607939_[SUMF1_(PROVISIONAL)_MULTIPLE_SULFATASE_DEFICIENCY,272200]
chr3	4536105	4536200	GS140127_01	96	1	3	6.51	0.020	chr3:4536105-4536200		ITPR1	ITPR1	147265_[ITPR1_(CONFIRMED)_SPINOCEREBELLAR_ATAXIA_15,606658|SPINOCEREBELLAR_ATAXIA_29,CONGENITAL_NONPROGRESSIVE,117360|GILLESPIE_SYNDROME,206700]
chr3	14219956	14220182	GS140127_01	227	1	1	-4.03	0.026	chr3:14219956-14220182		LSM3,XPC		613208_[XPC_(CONFIRMED)_XERODERMA_PIGMENTOSUM,GROUP_C,278720]
chr3	30715587	30715748	GS140127_01	162	1	3	3.74	0.007	chr3:30715587-30715748		TGFBR2	TGFBR2	190182_[TGFBR2_(CONFIRMED)_COLORECTAL_CANCER,HEREDITARY_NONPOLYPOSIS,TYPE_6,614331|ESOPHAGEAL_CANCER,SOMATIC,133239|LOEYS-DIETZ_SYNDROME_2,610168]
chr3	33093240	33093300	GS140127_01	61	1	3	5.47	0.039	chr3:33093240-33093300		GLB1		611458_[GLB1_(CONFIRMED)_GM1-GANGLIOSIDOSIS,TYPE_I,230500|GM1-GANGLIOSIDOSIS,TYPE_II,230600|GM1-GANGLIOSIDOSIS,TYPE_III,230650|MUCOPOLYSACCHARIDOSIS_TYPE_IVB_(MORQUIO),253010]
chr3	46620575	46620866	GS140127_01	292	2	3,3	6.52,3.29	0.020,0.020	chr3:46620575-46620647,chr3:46620712-46620866		LRRC2,TDGF1	TDGF1	187395_[TDGF1_(CONFIRMED)_FOREBRAIN_DEFECTS]
chr3	48619129	48619202	GS140127_01	74	1	3	5.25	0.026	chr3:48619129-48619202		COL7A1		120120_[COL7A1_(CONFIRMED)_EPIDERMOLYSIS_BULLOSA_DYSTROPHICA,AD,131750|EPIDERMOLYSIS_BULLOSA_DYSTROPHICA,AR,226600|EPIDERMOLYSIS_BULLOSA,PRETIBIAL,131850|EBD,BART_TYPE,132000|EBD,LOCALISATA_VARIANT|TRANSIENT_BULLOUS_OF_THE_NEWBORN,131705|EPIDERMOLYSIS_BULLOSA_PRURIGINOSA,604129|TOENAIL_DYSTROPHY,ISOLATED,607523|EBD_INVERSA,226600]
chr3	48626293	48626438	GS140127_01	146	1	1	-3.72	0.013	chr3:48626293-48626438		COL7A1		120120_[COL7A1_(CONFIRMED)_EPIDERMOLYSIS_BULLOSA_DYSTROPHICA,AD,131750|EPIDERMOLYSIS_BULLOSA_DYSTROPHICA,AR,226600|EPIDERMOLYSIS_BULLOSA,PRETIBIAL,131850|EBD,BART_TYPE,132000|EBD,LOCALISATA_VARIANT|TRANSIENT_BULLOUS_OF_THE_NEWBORN,131705|EPIDERMOLYSIS_BULLOSA_PRURIGINOSA,604129|TOENAIL_DYSTROPHY,ISOLATED,607523|EBD_INVERSA,226600]
chr3	128621386	128621481	GS140127_01	96	1	1	-3.65	0.026	chr3:128621386-128621481		ACAD9		611103_[ACAD9_(CONFIRMED)_MITOCHONDRIAL_COMPLEX_I_DEFICIENCY_DUE_TO_ACAD9_DEFICIENCY,611126]
chr3	139062851	139063050	GS140127_01	200	1	4	6.69	0.105	chr3:139062851-139063050		MRPS22		605810_[MRPS22_(CONFIRMED)_COMBINED_OXIDATIVE_PHOSPHORYLATION_DEFICIENCY_5,611719]
chr3	193335563	193335636	GS140127_01	74	1	3	4.00	0.013	chr3:193335563-193335636		OPA1	OPA1	605290_[OPA1_(CONFIRMED)_OPTIC_ATROPHY_1,165500|GLAUCOMA,NORMAL_TENSION,SUSCEPTIBILITY_TO,606657|OPTIC_ATROPHY_PLUS_SYNDROME,125250|BEHR_SYNDROME,210000|MITOCHONDRIAL_DNA_DEPLETION_SYNDROME_14_(ENCEPHALOCARDIOMYOPATHIC_TYPE),616896]
chr3	197024047	197024116	GS140127_01	70	1	4	6.26	0.046	chr3:197024047-197024116		DLG1	DLG1	
chr3	197404341	197404422	GS140127_01	82	1	3	7.26	0.033	chr3:197404341-197404422		RUBCN		613516_[KIAA0226_(PROVISIONAL)_SPINOCEREBELLAR_ATAXIA,AUTOSOMAL_RECESSIVE_15,615705]
chr3	197410168	197410320	GS140127_01	153	1	3	4.56	0.059	chr3:197410168-197410320		RUBCN		613516_[KIAA0226_(PROVISIONAL)_SPINOCEREBELLAR_ATAXIA,AUTOSOMAL_RECESSIVE_15,615705]
chr4	1900938	1901132	GS140127_01	195	1	3	4.02	0.059	chr4:1900938-1901132		NSD2	NSD2	
chr4	15471479	15471691	GS140127_01	213	1	3	3.61	0.033	chr4:15471479-15471691		CC2D2A	CC2D2A	612013_[CC2D2A_(CONFIRMED)_JOUBERT_SYNDROME_9,612285|MECKEL_SYNDROME_6,612284|COACH_SYNDROME,216360]
chr4	17492275	17492378	GS140127_01	104	1	3	4.34	0.059	chr4:17492275-17492378		QDPR		612676_[QDPR_(CONFIRMED)_HYPERPHENYLALANINEMIA,BH4-DEFICIENT,C,261630]
chr4	79203964	79204131	GS140127_01	168	1	3	4.80	0.098	chr4:79203964-79204131		FRAS1		607830_[FRAS1_(PROVISIONAL)_FRASER_SYNDROME,219000]
chr4	107236757	107236803	GS140127_01	47	1	4	6.16	0.078	chr4:107236757-107236803		AIMP1,TBCK		603605_[AIMP1_(PROVISIONAL)_LEUKODYSTROPHY,HYPOMYELINATING,3,260600],616899_[TBCK_(PROVISIONAL)_HYPOTONIA,INFANTILE,WITH_PSYCHOMOTOR_RETARDATION_AND_CHARACTERISTIC_FACIES_3,616900]
chr4	146575136	146575305	GS140127_01	170	1	3	4.82	0.039	chr4:146575136-146575305		MMAA		607481_[MMAA_(PROVISIONAL)_METHYLMALONIC_ACIDURIA,VITAMIN_B12-RESPONSIVE,251100]
chr4	186990299	186990412	GS140127_01	114	1	3	3.69	0.033	chr4:186990299-186990412		TLR3		603029_[TLR3_(PROVISIONAL)_HERPES_SIMPLEX_ENCEPHALITIS,SUSCEPTIBILITY_TO,2_613002|HIV1_INFECTION,RESISTANCE_TO,609423]
chr5	52404342	52405335	GS140127_01	994	2	3,4	2.62,5.11	0.039,0.078	chr5:52404342-52404483,chr5:52405071-52405335		MOCS2		603708_[MOCS2_(PROVISIONAL)_MOLYBDENUM_COFACTOR_DEFICIENCY_B,252160]
chr5	74012402	74012508	GS140127_01	107	1	3	3.70	0.020	chr5:74012402-74012508		HEXB	HEXB	606873_[HEXB_(CONFIRMED)_SANDHOFF_DISEASE,INFANTILE,JUVENILE,AND_ADULT_FORMS,268800]
chr5	88026018	88026061	GS140127_01	44	1	3	4.07	0.020	chr5:88026018-88026061		MEF2C	MEF2C	600662_[MEF2C_(CONFIRMED)_MENTAL_RETARDATION,STEREOTYPIC_MOVEMENTS,EPILEPSY,AND/OR_CEREBRAL_MALFORMATIONS,613443|CHROMOSOME_5Q14.3_DELETION_SYNDROME,613443]
chr5	90098546	90098709	GS140127_01	164	1	3	3.53	0.013	chr5:90098546-90098709		ADGRV1	ADGRV1	602851_[GPR98_(CONFIRMED)_FEBRILE_SEIZURES,FAMILIAL,4,604352|USHER_SYNDROME,TYPE_2C,605472|USHER_SYNDROME,TYPE_2C,GPR98/PDZD7_DIGENIC,605472]
chr5	132202309	132202737	GS140127_01	429	2	3,3	2.00,3.74	0.039,0.033	chr5:132202309-132202389,chr5:132202551-132202737		GDF9,UQCRQ		612080_[UQCRQ_(PROVISIONAL)_MITOCHONDRIAL_COMPLEX_III_DEFICIENCY,NUCLEAR_TYPE_4,615159]
chr5	146460612	146460709	GS140127_01	98	1	3	4.50	0.013	chr5:146460612-146460709		PPP2R2B		604325_[PPP2R2B_(PROVISIONAL)_SPINOCEREBELLAR_ATAXIA_12,604326]
chr6	32805304	32805438	GS140127_01	135	1	3	3.86	0.033	chr6:32805304-32805438		TAP2		170261_[TAP2_(CONFIRMED)_BARE_LYMPHOCYTE_SYNDROME,TYPE_I,DUE_TO_TAP2_DEFICIENCY,604571|WEGENER-LIKE_GRANULOMATOSIS]
chr6	32819876	32820289	GS140127_01	414	2	3,3	4.20,4.07	0.026,0.026	chr6:32819876-32820026,chr6:32820155-32820289		PSMB9,TAP1		170260_[TAP1_(CONFIRMED)_BARE_LYMPHOCYTE_SYNDROME,TYPE_I,604571]
chr6	52925724	52925854	GS140127_01	131	1	3	3.57	0.020	chr6:52925724-52925854		ICK		612325_[ICK_(PROVISIONAL)_ENDOCRINE-CEREBROOSTEODYSPLASIA,612651]
chr6	88258299	88258374	GS140127_01	76	1	3	3.72	0.013	chr6:88258299-88258374		RARS2		611524_[RARS2_(CONFIRMED)_PONTOCEREBELLAR_HYPOPLASIA,TYPE_6,611523]
chr6	157431596	157431705	GS140127_01	110	1	3	4.67	0.039	chr6:157431596-157431705		ARID1B	ARID1B	614556_[ARID1B_(CONFIRMED)_COFFIN-SIRIS_SYNDROME_1,135900]
chr7	73474460	73474841	GS140127_01	382	2	1,1	-3.00,-4.21	0.020,0.078	chr7:73474460-73474524,chr7:73474696-73474841		ELN	ELN	130160_[ELN_(CONFIRMED)_SUPRAVALVAR_AORTIC_STENOSIS,185500|CUTIS_LAXA,AUTOSOMAL_DOMINANT,123700],608512_[NCF1_(PROVISIONAL)_CHRONIC_GRANULOMATOUS_DISEASE_DUE_TO_DEFICIENCY_OF_NCF-1,233700]
chr7	127983720	127983972	GS140127_01	253	1	3	3.84	0.105	chr7:127983720-127983972		RBM28		612074_[RBM28_(CONFIRMED)_ALOPECIA,NEUROLOGIC_DEFECTS,AND_ENDOCRINOPATHY_SYNDROME,612079]
chr7	128480592	128481034	GS140127_01	443	2	1,1	-3.14,-4.47	0.013,0.020	chr7:128480592-128480738,chr7:128480878-128481034	yes	FLNC		102565_[FLNC_(CONFIRMED)_MYOPATHY,MYOFIBRILLAR,5,609524|MYOPATHY,DISTAL,4,614065|CARDIOMYOPATHY,FAMILIAL_HYPERTROPHIC,26|CARDIOMYOPATHY,FAMILIAL_RESTRICTIVE_5,617047]
chr7	142986671	142986759	GS140127_01	89	1	3	3.77	0.046	chr7:142986671-142986759		CASP2		
chr8	43048890	43048996	GS140127_01	107	1	3	4.74	0.026	chr8:43048890-43048996		HGSNAT		610453_[HGSNAT_(CONFIRMED)_MUCOPOLYSACCHARIDOSIS_TYPE_IIIC_(SANFILIPPO_C),252930|RETINITIS_PIGMENTOSA_73,616544]
chr8	48869905	48870001	GS140127_01	97	1	3	3.72	0.013	chr8:48869905-48870001		PRKDC		600899_[PRKDC_(CONFIRMED)_IMMUNODEFICIENCY_26,WITH_OR_WITHOUT_NEUROLOGIC_ABNORMALITIES,615966]
chr8	100830669	100831126	GS140127_01	458	2	3,3	4.54,2.89	0.020,0.020	chr8:100830669-100830772,chr8:100830931-100831126		VPS13B	VPS13B	607817_[VPS13B_(CONFIRMED)_COHEN_SYNDROME,216550]
chr8	100871522	100871718	GS140127_01	197	1	3	4.11	0.039	chr8:100871522-100871718		VPS13B	VPS13B	607817_[VPS13B_(CONFIRMED)_COHEN_SYNDROME,216550]
chr8	140744212	140744455	GS140127_01	244	1	3	5.97	0.072	chr8:140744212-140744455		TRAPPC9		611966_[TRAPPC9_(PROVISIONAL)_MENTAL_RETARDATION,AUTOSOMAL_RECESSIVE_13,613192]
chr9	470284	470692	GS140127_01	409	2	5,3	10.00,4.66	0.052,0.039	chr9:470284-470384,chr9:470546-470692		KANK1	KANK1	607704_[KANK1_(CONFIRMED)_CEREBRAL_PALSY,SPASTIC_QUADRIPLEGIC,2,612900]
chr9	6588391	6588452	GS140127_01	62	1	3	3.73	0.026	chr9:6588391-6588452		GLDC		238300_[GLDC_(CONFIRMED)_GLYCINE_ENCEPHALOPATHY,605899]
chr9	34647076	34647574	GS140127_01	499	2	3,3	4.00,2.25	0.059,0.020	chr9:34647076-34647265,chr9:34647479-34647574		GALT		606999_[GALT_(CONFIRMED)_GALACTOSEMIA,230400]
chr9	123744112	123744227	GS140127_01	116	1	3	4.60	0.007	chr9:123744112-123744227		C5		120900_[C5_(CONFIRMED)_C5_DEFICIENCY,609536|ECULIZUMAB,POOR_RESPONSE_TO,615749]
chr9	124062324	124064455	GS140127_01	2132	2	1,1	-3.51,-2.62	0.046,0.033	chr9:124062324-124062414,chr9:124064231-124064455		GSN		137350_[GSN_(PROVISIONAL)_AMYLOIDOSIS,FINNISH_TYPE,105120]
chr9	136433715	136433890	GS140127_01	176	1	1	-3.75	0.046	chr9:136433715-136433890		ADAMTSL2		612277_[ADAMTSL2_(PROVISIONAL)_GELEOPHYSIC_DYSPLASIA_1,231050]
chr10	43615519	43615661	GS140127_01	143	1	1	-3.55	0.059	chr10:43615519-43615661		RET	RET	164761_[RET_(CONFIRMED)_MULTIPLE_ENDOCRINE_NEOPLASIA_IIA,171400|MEDULLARY_THYROID_CARCINOMA,155240|MULTIPLE_ENDOCRINE_NEOPLASIA_IIB,162300|CENTRAL_HYPOVENTILATION_SYNDROME,CONGENITAL,209880|PHEOCHROMOCYTOMA,171300|HIRSCHSPRUNG_DISEASE,SUSCEPTIBILITY_TO,1,142623]
chr10	64575611	64576136	GS140127_01	526	1	3	3.84	0.020	chr10:64575611-64576136		EGR2		129010_[EGR2_(PROVISIONAL)_NEUROPATHY,CONGENITAL_HYPOMYELINATING,1,605253|CHARCOT-MARIE-TOOTH_DISEASE,TYPE_1D,607678|DEJERINE-SOTTAS_DISEASE,145900]
chr10	76074415	76074513	GS140127_01	99	1	3	4.01	0.052	chr10:76074415-76074513		ADK		102750_[ADK_(CONFIRMED)_HYPERMETHIONINEMIA_DUE_TO_ADENOSINE_KINASE_DEFICIENCY,614300]
chr10	88466278	88469817	GS140127_01	3540	2	1,1	-3.59,-2.78	0.026,0.033	chr10:88466278-88466486,chr10:88469652-88469817		LDB3		605906_[LDB3_(CONFIRMED)_MYOPATHY,MYOFIBRILLAR,4,609452|CARDIOMYOPATHY,DILATED,1C,WITH_OR_WITHOUT_LVNC,601493|CARDIOMYOPATHY,HYPERTROPHIC,24,601493|LEFT_VENTRICULAR_NONCOMPACTION_3,601493]
chr10	97515399	97515533	GS140127_01	135	1	3	3.83	0.052	chr10:97515399-97515533		ENTPD1,ENTPD1-AS1		601752_[ENTPD1_(PROVISIONAL)_SPASTIC_PARAPLEGIA_64,AUTOSOMAL_RECESSIVE,615683]
chr11	1780736	1780879	GS140127_01	144	1	1	-3.62	0.118	chr11:1780736-1780879		CTSD		116840_[CTSD_(CONFIRMED)_CEROID_LIPOFUSCINOSIS,NEURONAL,10,610127]
chr11	44296888	44297218	GS140127_01	331	1	1	-3.67	0.013	chr11:44296888-44297218		ALX4	ALX4	605420_[ALX4_(PROVISIONAL)_PARIETAL_FORAMINA_2,609597|FRONTONASAL_DYSPLASIA_2,613451|CRANIOSYNOSTOSIS_5,SUSCEPTIBILITY_TO,615529]
chr11	47236483	47238033	GS140127_01	1551	2	3,3	3.90,3.78	0.046,0.052	chr11:47236483-47236824,chr11:47237877-47238033		DDB2		600811_[DDB2_(PROVISIONAL)_XERODERMA_PIGMENTOSUM,GROUP_E,DDB-NEGATIVE_SUBTYPE,278740]
chr11	61160693	61160814	GS140127_01	122	1	3	3.73	0.013	chr11:61160693-61160814		TMEM216		613277_[TMEM216_(CONFIRMED)_JOUBERT_SYNDROME_2,608091|MECKEL_SYNDROME_2,603194]
chr11	65487506	65487645	GS140127_01	140	1	3	3.60	0.039	chr11:65487506-65487645		RNASEH2C		610330_[RNASEH2C_(PROVISIONAL)_AICARDI-GOUTIERES_SYNDROME_3,610329]
chr11	66278109	66278187	GS140127_01	79	1	4	5.69	0.052	chr11:66278109-66278187		BBS1		209901_[BBS1_(CONFIRMED)_BARDET-BIEDL_SYNDROME_1,209900]
chr11	77850530	86749238	GS140127_01	8898709	2	4,3	8.48,2.09	0.065,0.046	chr11:77850530-77850709,chr11:86748876-86749238		ALG8,TMEM135		608103_[ALG8_(PROVISIONAL)_CONGENITAL_DISORDER_OF_GLYCOSYLATION,TYPE_IH,608104]
chr11	108005859	108005979	GS140127_01	121	1	3	3.63	0.013	chr11:108005859-108005979		ACAT1		607809_[ACAT1_(CONFIRMED)_ALPHA-METHYLACETOACETIC_ACIDURIA,203750]
chr11	111741488	111742014	GS140127_01	527	1	3	5.12	0.039	chr11:111741488-111742014		ALG9		606941_[ALG9_(CONFIRMED)_CONGENITAL_DISORDER_OF_GLYCOSYLATION,TYPE_IL,608776|GILLESSEN-KAESBACH-NISHIMURA_SYNDROME,263210]
chr11	111742065	111742315	GS140127_01	251	1	1	-3.53	0.033	chr11:111742065-111742315		ALG9		606941_[ALG9_(CONFIRMED)_CONGENITAL_DISORDER_OF_GLYCOSYLATION,TYPE_IL,608776|GILLESSEN-KAESBACH-NISHIMURA_SYNDROME,263210]
chr12	6442225	6442323	GS140127_01	99	1	3	3.76	0.026	chr12:6442225-6442323		TNFRSF1A		191190_[TNFRSF1A_(CONFIRMED)_PERIODIC_FEVER,FAMILIAL,142680|MULTIPLE_SCLEROSIS,SUSCEPTIBILITY_TO,5,614810]
chr12	7341749	7342137	GS140127_01	389	1	3	3.82	0.039	chr12:7341749-7342137		PEX5		600414_[PEX5_(CONFIRMED)_PEROXISOME_BIOGENESIS_DISORDER_2A_(ZELLWEGER),214110|PEROXISOME_BIOGENESIS_DISORDER_2B,202370|RHIZOMELIC_CHONDRODYSPLASIA_PUNCTATA,TYPE_5,616716]
chr12	32906842	32907029	GS140127_01	188	1	3	3.79	0.013	chr12:32906842-32907029		YARS2		610957_[YARS2_(PROVISIONAL)_MYOPATHY,LACTIC_ACIDOSIS,AND_SIDEROBLASTIC_ANEMIA_2,613561]
chr12	44152737	44152829	GS140127_01	93	1	4	7.78	0.052	chr12:44152737-44152829		IRAK4		606883_[IRAK4_(PROVISIONAL)_IRAK4_DEFICIENCY,607676|INVASIVE_PNEUMOCOCCAL_DISEASE,RECURRENT_ISOLATED,1,610799]
chr12	51019749	51019840	GS140127_01	92	1	3	4.87	0.039	chr12:51019749-51019840		DIP2B		611379_[DIP2B_(PROVISIONAL)_MENTAL_RETARDATION,FRA12A_TYPE,136630]
chr12	58176518	58176651	GS140127_01	134	1	3	6.95	0.092	chr12:58176518-58176651		TSFM		604723_[TSFM_(CONFIRMED)_COMBINED_OXIDATIVE_PHOSPHORYLATION_DEFICIENCY_3,610505]
chr12	65138579	65138697	GS140127_01	119	1	3	3.86	0.020	chr12:65138579-65138697		GNS		607664_[GNS_(PROVISIONAL)_MUCOPOLYSACCHARIDOSIS_TYPE_IIID,252940]
chr12	102151340	102151445	GS140127_01	106	1	3	3.80	0.046	chr12:102151340-102151445		GNPTAB		607840_[GNPTAB_(CONFIRMED)_MUCOLIPIDOSIS_III_ALPHA/BETA,252600|MUCOLIPIDOSIS_II_ALPHA/BETA,252500]
chr13	23894766	23894909	GS140127_01	144	1	3	3.54	0.013	chr13:23894766-23894909		SGCG		608896_[SGCG_(CONFIRMED)_MUSCULAR_DYSTROPHY,LIMB-GIRDLE,TYPE_2C,253700]
chr14	35182870	35183033	GS140127_01	164	1	3	5.71	0.020	chr14:35182870-35183033		CFL2		601443_[CFL2_(CONFIRMED)_NEMALINE_MYOPATHY_7,AUTOSOMAL_RECESSIVE,610687]
chr14	55312476	55312580	GS140127_01	105	1	3	4.45	0.020	chr14:55312476-55312580		GCH1		600225_[GCH1_(PROVISIONAL)_DYSTONIA,DOPA-RESPONSIVE,WITH_OR_WITHOUT_HYPERPHENYLALANINEMIA,128230|HYPERPHENYLALANINEMIA,BH4-DEFICIENT,B,233910]
chr14	64375806	64375955	GS140127_01	150	1	3	3.67	0.020	chr14:64375806-64375955		SYNE2		608442_[SYNE2_(PROVISIONAL)_EMERY-DREIFUSS_MUSCULAR_DYSTROPHY_5,AUTOSOMAL_DOMINANT,612999]
chr14	77745062	77745222	GS140127_01	161	1	1	-4.28	0.026	chr14:77745062-77745222		POMT2		607439_[POMT2_(CONFIRMED)_MUSCULAR_DYSTROPHY-DYSTROGLYCANOPATHY_(CONGENITAL_WITH_BRAIN_AND_EYE_ANOMALIES),TYPE_A,2,613150|MUSCULAR_DYSTROPHY-DYSTROGLYCANOPATHY_(CONGENITAL_WITH_MENTAL_RETARDATION),TYPE_B,2,613156|MUSCULAR_DYSTROPHY-DYSTROGLYCANOPATHY_(LIMB-GIRDLE),TYPE_C,2,613158]
chr14	77915626	77915710	GS140127_01	85	1	3	4.53	0.026	chr14:77915626-77915710		VIPAS39		613401_[VIPAS39_(PROVISIONAL)_ARTHROGRYPOSIS,RENAL_DYSFUNCTION,AND_CHOLESTASIS_2,613404]
chr15	34610752	34629055	GS140127_01	18304	2	3,3	4.91,3.05	0.078,0.026	chr15:34610752-34611031,chr15:34628601-34629055		SLC12A6		604878_[SLC12A6_(CONFIRMED)_AGENESIS_OF_THE_CORPUS_CALLOSUM_WITH_PERIPHERAL_NEUROPATHY,218000]
chr15	49089848	49089937	GS140127_01	90	1	3	4.37	0.039	chr15:49089848-49089937		CEP152		613529_[CEP152_(PROVISIONAL)_MICROCEPHALY_9,PRIMARY,AUTOSOMAL_RECESSIVE,614852|SECKEL_SYNDROME_5,613823]
chr15	51233853	51233982	GS140127_01	130	1	3	3.56	0.007	chr15:51233853-51233982		AP4E1		607244_[AP4E1_(PROVISIONAL)_SPASTIC_PARAPLEGIA_51,AUTOSOMAL_RECESSIVE,613744|STUTTERING,FAMILIAL_PERSISTENT,1,184450]
chr15	74495334	74495566	GS140127_01	233	1	3	3.66	0.033	chr15:74495334-74495566		STRA6		610745_[STRA6_(PROVISIONAL)_MICROPHTHALMIA,SYNDROMIC_9,601186|MICROPHTHALMIA,ISOLATED,WITH_COLOBOMA_8,601186]
chr15	91565374	91565843	GS140127_01	470	1	3	4.93	0.039	chr15:91565374-91565843		VPS33B		608552_[VPS33B_(PROVISIONAL)_ARTHROGRYPOSIS,RENAL_DYSFUNCTION,AND_CHOLESTASIS_1,208085]
chr16	5129739	5131067	GS140127_01	1329	2	1,1	-2.91,-3.86	0.020,0.046	chr16:5129739-5129818,chr16:5130937-5131067		ALG1		605907_[ALG1_(PROVISIONAL)_CONGENITAL_DISORDER_OF_GLYCOSYLATION,TYPE_IK,608540]
chr16	28947823	28947931	GS140127_01	109	1	3	5.18	0.033	chr16:28947823-28947931		CD19		107265_[CD19_(PROVISIONAL)_IMMUNODEFICIENCY,COMMON_VARIABLE,3,613493]
chr16	28949984	28950309	GS140127_01	326	2	1,1	-2.21,-3.78	0.026,0.013	chr16:28949984-28950099,chr16:28950183-28950309		CD19		107265_[CD19_(PROVISIONAL)_IMMUNODEFICIENCY,COMMON_VARIABLE,3,613493]
chr16	30198693	30198832	GS140127_01	140	1	4	4.33	0.026	chr16:30198693-30198832	yes	CORO1A		605000_[CORO1A_(PROVISIONAL)_IMMUNODEFICIENCY_8,615401]
chr16	31199636	31199688	GS140127_01	53	1	3	3.98	0.039	chr16:31199636-31199688		FUS		137070_[FUS_(CONFIRMED)_AMYOTROPHIC_LATERAL_SCLEROSIS_6,WITH_OR_WITHOUT_FRONTOTEMPORAL_DEMENTIA,608030|TREMOR,HEREDITARY_ESSENTIAL,4,614782]
chr16	66551029	66551128	GS140127_01	100	1	4	6.77	0.039	chr16:66551029-66551128		TK2		188250_[TK2_(CONFIRMED)_MITOCHONDRIAL_DNA_DEPLETION_SYNDROME_2_(MYOPATHIC_TYPE),609560|PROGRESSIVE_EXTERNAL_OPHTHALMOPLEGIA_WITH_MITOCHONDRIAL_DNA_DELETIONS,AUTOSOMAL_RECESSIVE_3,617069]
chr17	38804015	38804113	GS140127_01	99	1	3	4.51	0.033	chr17:38804015-38804113		KRT222,SMARCE1		603111_[SMARCE1_(PROVISIONAL)_MENINGIOMA,FAMILIAL,SUSCEPTIBILITY_TO,607174|COFFIN-SIRIS_SYNDROME_5,616938]
chr17	40370731	40370906	GS140127_01	176	1	1	-3.91	0.046	chr17:40370731-40370906		STAT5B		604260_[STAT5B_(PROVISIONAL)_LEUKEMIA,ACUTE_PROMYELOCYTIC,SOMATIC,102578|GROWTH_HORMONE_INSENSITIVITY_WITH_IMMUNODEFICIENCY,245590]
chr17	40371720	40371870	GS140127_01	151	1	1	-3.55	0.065	chr17:40371720-40371870		STAT5B		604260_[STAT5B_(PROVISIONAL)_LEUKEMIA,ACUTE_PROMYELOCYTIC,SOMATIC,102578|GROWTH_HORMONE_INSENSITIVITY_WITH_IMMUNODEFICIENCY,245590]
chr17	40695036	42083289	GS140127_01	1388254	2	1,1	-2.49,-3.52	0.007,0.124	chr17:40695036-40696476,chr17:42082995-42083289		NAGLU,NAGS		608300_[NAGS_(CONFIRMED)_N-ACETYLGLUTAMATE_SYNTHASE_DEFICIENCY,237310],609701_[NAGLU_(CONFIRMED)_MUCOPOLYSACCHARIDOSIS_TYPE_IIIB_(SANFILIPPO_B),252920|CHARCOT-MARIE-TOOTH_DISEASE,AXONAL,TYPE_2V,616491]
chr17	57078949	57079085	GS140127_01	137	1	3	3.95	0.065	chr17:57078949-57079085		TRIM37		605073_[TRIM37_(CONFIRMED)_MULIBREY_NANISM,253250]
chr17	62009545	62009714	GS140127_01	170	1	3	4.22	0.013	chr17:62009545-62009714		CD79B		147245_[CD79B_(PROVISIONAL)_AGAMMAGLOBULINEMIA_6,612692]
chr17	62479026	62479126	GS140127_01	101	1	4	4.09	0.137	chr17:62479026-62479126		POLG2		604983_[POLG2_(PROVISIONAL)_PROGRESSIVE_EXTERNAL_OPHTHALMOPLEGIA_WITH_MITOCHONDRIAL_DNA_DELETIONS,AUTOSOMAL_DOMINANT_4,610131]
chr17	62488774	62489148	GS140127_01	375	2	6,3	10.00,4.51	0.098,0.046	chr17:62488774-62488899,chr17:62489002-62489148		POLG2		604983_[POLG2_(PROVISIONAL)_PROGRESSIVE_EXTERNAL_OPHTHALMOPLEGIA_WITH_MITOCHONDRIAL_DNA_DELETIONS,AUTOSOMAL_DOMINANT_4,610131]
chr18	3447598	3447805	GS140127_01	208	1	3	5.85	0.033	chr18:3447598-3447805		TGIF1	TGIF1	602630_[TGIF1_(CONFIRMED)_HOLOPROSENCEPHALY_4,142946]
chr18	3453762	3453864	GS140127_01	103	1	3	4.20	0.039	chr18:3453762-3453864		TGIF1	TGIF1	602630_[TGIF1_(CONFIRMED)_HOLOPROSENCEPHALY_4,142946]
chr18	9119314	9119598	GS140127_01	285	2	3,3	3.79,2.69	0.059,0.052	chr18:9119314-9119396,chr18:9119462-9119598		NDUFV2		600532_[NDUFV2_(CONFIRMED)_MITOCHONDRIAL_COMPLEX_I_DEFICIENCY,252010]
chr18	21119309	21119444	GS140127_01	136	1	3	3.80	0.020	chr18:21119309-21119444		NPC1		607623_[NPC1_(CONFIRMED)_NIEMANN-PICK_DISEASE,TYPE_C1,257220|NIEMANN-PICK_DISEASE,TYPE_D,257220]
chr18	21120402	21121182	GS140127_01	781	2	3,3	6.86,3.61	0.020,0.013	chr18:21120402-21120511,chr18:21121022-21121182		NPC1		607623_[NPC1_(CONFIRMED)_NIEMANN-PICK_DISEASE,TYPE_C1,257220|NIEMANN-PICK_DISEASE,TYPE_D,257220]
chr18	21393011	21393077	GS140127_01	67	1	3	4.04	0.020	chr18:21393011-21393077		LAMA3		600805_[LAMA3_(PROVISIONAL)_EPIDERMOLYSIS_BULLOSA,JUNCTIONAL,HERLITZ_TYPE,226700|EPIDERMOLYSIS_BULLOSA,GENERALIZED_ATROPHIC_BENIGN,226650|LARYNGOONYCHOCUTANEOUS_SYNDROME,245660]
chr18	21426251	21426482	GS140127_01	232	1	3	3.71	0.085	chr18:21426251-21426482		LAMA3		600805_[LAMA3_(PROVISIONAL)_EPIDERMOLYSIS_BULLOSA,JUNCTIONAL,HERLITZ_TYPE,226700|EPIDERMOLYSIS_BULLOSA,GENERALIZED_ATROPHIC_BENIGN,226650|LARYNGOONYCHOCUTANEOUS_SYNDROME,245660]
chr18	33722234	33722320	GS140127_01	87	1	3	3.62	0.013	chr18:33722234-33722320		ELP2		616054_[ELP2_(PROVISIONAL)_MENTAL_RETARDATION,AUTOSOMAL_RECESSIVE_58,617270]
chr18	53255259	53255870	GS140127_01	612	1	3	4.43	0.033	chr18:53255259-53255870		TCF4	TCF4	602272_[TCF4_(CONFIRMED)_PITT-HOPKINS_SYNDROME,610954|CORNEAL_DYSTROPHY,FUCHS_ENDOTHELIAL,3,613267]
chr19	12776156	12776629	GS140127_01	474	2	3,3	4.02,3.94	0.033,0.026	chr19:12776156-12776349,chr19:12776507-12776629		MAN2B1		609458_[MAN2B1_(CONFIRMED)_MANNOSIDOSIS,ALPHA-,TYPES_I_AND_II,248500]
chr19	13008107	13008252	GS140127_01	146	1	1	-3.73	0.020	chr19:13008107-13008252		GCDH		608801_[GCDH_(CONFIRMED)_GLUTARICACIDURIA,TYPE_I,231670]
chr19	14029933	14030025	GS140127_01	93	1	1	-3.88	0.196	chr19:14029933-14030025		CC2D1A		610055_[CC2D1A_(PROVISIONAL)_MENTAL_RETARDATION,AUTOSOMAL_RECESSIVE_3,608443]
chr19	15289624	15289762	GS140127_01	139	1	1	-3.58	0.007	chr19:15289624-15289762		NOTCH3	NOTCH3	600276_[NOTCH3_(CONFIRMED)_CEREBRAL_ARTERIOPATHY_WITH_SUBCORTICAL_INFARCTS_AND_LEUKOENCEPHALOPATHY_1,125310|MYOFIBROMATOSIS,INFANTILE_2,615293|LATERAL_MENINGOCELE_SYNDROME,130720]
chr19	15298682	15298815	GS140127_01	134	1	3	3.55	0.065	chr19:15298682-15298815		NOTCH3	NOTCH3	600276_[NOTCH3_(CONFIRMED)_CEREBRAL_ARTERIOPATHY_WITH_SUBCORTICAL_INFARCTS_AND_LEUKOENCEPHALOPATHY_1,125310|MYOFIBROMATOSIS,INFANTILE_2,615293|LATERAL_MENINGOCELE_SYNDROME,130720]
chr19	19307762	19307865	GS140127_01	104	1	3	3.99	0.052	chr19:19307762-19307865		RFXANK		603200_[RFXANK_(PROVISIONAL)_MHC_CLASS_II_DEFICIENCY,COMPLEMENTATION_GROUP_B,209920]
chr19	36591640	36592686	GS140127_01	1047	3	1,1,1	-2.03,-4.18,-2.40	0.020,0.020,0.039	chr19:36591640-36591787,chr19:36592106-36592229,chr19:36592556-36592686		WDR62		613583_[WDR62_(CONFIRMED)_MICROCEPHALY_2,PRIMARY,AUTOSOMAL_RECESSIVE,WITH_OR_WITHOUT_CORTICAL_MALFORMATIONS,604317]
chr19	38932979	38934282	GS140127_01	1304	2	1,1	-3.53,-3.23	0.046,0.020	chr19:38932979-38933103,chr19:38934188-38934282		RYR1		180901_[RYR1_(CONFIRMED)_MALIGNANT_HYPERTHERMIA_SUSCEPTIBILITY_1,145600|CENTRAL_CORE_DISEASE,117000|MINICORE_MYOPATHY_WITH_EXTERNAL_OPHTHALMOPLEGIA,255320|NEUROMUSCULAR_DISEASE,CONGENITAL,WITH_UNIFORM_TYPE_1_FIBER,117000|KING-DENBOROUGH_SYNDROME,145600]
chr19	39002702	39002782	GS140127_01	81	1	1	-3.84	0.065	chr19:39002702-39002782		RYR1		180901_[RYR1_(CONFIRMED)_MALIGNANT_HYPERTHERMIA_SUSCEPTIBILITY_1,145600|CENTRAL_CORE_DISEASE,117000|MINICORE_MYOPATHY_WITH_EXTERNAL_OPHTHALMOPLEGIA,255320|NEUROMUSCULAR_DISEASE,CONGENITAL,WITH_UNIFORM_TYPE_1_FIBER,117000|KING-DENBOROUGH_SYNDROME,145600]
chr19	39014545	39016152	GS140127_01	1608	2	1,1	-3.89,-3.40	0.065,0.026	chr19:39014545-39014579,chr19:39015962-39016152		RYR1		180901_[RYR1_(CONFIRMED)_MALIGNANT_HYPERTHERMIA_SUSCEPTIBILITY_1,145600|CENTRAL_CORE_DISEASE,117000|MINICORE_MYOPATHY_WITH_EXTERNAL_OPHTHALMOPLEGIA,255320|NEUROMUSCULAR_DISEASE,CONGENITAL,WITH_UNIFORM_TYPE_1_FIBER,117000|KING-DENBOROUGH_SYNDROME,145600]
chr19	41893409	41893518	GS140127_01	110	1	1	-3.67	0.033	chr19:41893409-41893518		BCKDHA,EXOSC5		608348_[BCKDHA_(CONFIRMED)_MAPLE_SYRUP_URINE_DISEASE,TYPE_IA,248600]
chr19	41903684	41903850	GS140127_01	167	1	4	5.75	0.059	chr19:41903684-41903850		BCKDHA		608348_[BCKDHA_(CONFIRMED)_MAPLE_SYRUP_URINE_DISEASE,TYPE_IA,248600]
chr19	44030343	44030821	GS140127_01	479	2	3,3	6.17,3.29	0.026,0.052	chr19:44030343-44030511,chr19:44030657-44030821		ETHE1,ZNF575		608451_[ETHE1_(PROVISIONAL)_ETHYLMALONIC_ENCEPHALOPATHY,602473]
chr19	45926518	45926830	GS140127_01	313	1	3	3.95	0.092	chr19:45926518-45926830		ERCC1		126380_[ERCC1_(CONFIRMED)_CEREBROOCULOFACIOSKELETAL_SYNDROME_4,610758]
chr19	50432573	50432998	GS140127_01	426	1	1	-3.52	0.033	chr19:50432573-50432998		ATF5,IL4I1,NUP62		605815_[NUP62_(CONFIRMED)_STRIATONIGRAL_DEGENERATION,INFANTILE,271930]
chr19	51869514	51869682	GS140127_01	169	1	5	7.07	0.065	chr19:51869514-51869682		ETFB		130410_[ETFB_(CONFIRMED)_GLUTARIC_ACIDEMIA_IIB,231680]
chr19	54401684	54401892	GS140127_01	209	1	1	-3.59	0.059	chr19:54401684-54401892		PRKCG		176980_[PRKCG_(CONFIRMED)_SPINOCEREBELLAR_ATAXIA_14,605361]
chr20	31381332	31381411	GS140127_01	80	1	3	4.27	0.007	chr20:31381332-31381411		DNMT3B	DNMT3B	602900_[DNMT3B_(CONFIRMED)_IMMUNODEFICIENCY-CENTROMERIC_INSTABILITY-FACIAL_ANOMALIES_SYNDROME_1,242860]
chr20	33524556	33524653	GS140127_01	98	1	3	3.71	0.013	chr20:33524556-33524653		GSS		601002_[GSS_(PROVISIONAL)_HEMOLYTIC_ANEMIA_DUE_TO_GLUTATHIONE_SYNTHETASE_DEFICIENCY,231900|GLUTATHIONE_SYNTHETASE_DEFICIENCY,266130]
chr20	35555575	35559288	GS140127_01	3714	2	3,3	4.24,4.02	0.033,0.046	chr20:35555575-35555665,chr20:35559153-35559288		SAMHD1		606754_[SAMHD1_(PROVISIONAL)_AICARDI-GOUTIERES_SYNDROME_5,612952|CHILBLAIN_LUPUS_2,614415]
chr21	46308598	46308820	GS140127_01	223	1	1	-3.54	0.026	chr21:46308598-46308820		ITGB2		600065_[ITGB2_(CONFIRMED)_LEUKOCYTE_ADHESION_DEFICIENCY,116920]
chr21	46898231	46898277	GS140127_01	47	1	4	8.40	0.052	chr21:46898231-46898277		COL18A1		120328_[COL18A1_(CONFIRMED)_KNOBLOCH_SYNDROME,TYPE_1,267750]
chr22	38577661	38577846	GS140127_01	186	2	4,3	6.73,3.59	0.072,0.078	chr22:38577661-38577771,chr22:38577781-38577846		PLA2G6		603604_[PLA2G6_(CONFIRMED)_INFANTILE_NEUROAXONAL_DYSTROPHY_1,256600|NEURODEGENERATION_WITH_BRAIN_IRON_ACCUMULATION_2B,610217|PARKINSON_DISEASE_14,AUTOSOMAL_RECESSIVE,612953]
chr22	41256672	41256807	GS140127_01	136	1	4	6.03	0.092	chr22:41256672-41256807		DNAJB7,XPNPEP3		613553_[XPNPEP3_(CONFIRMED)_NEPHRONOPHTHISIS-LIKE_NEPHROPATHY_1,613159]
chr22	42523439	42526893	GS140127_01	3455	5	1,1,1,1,1	-2.35,-4.47,-4.33,-4.47,-2.41	0.137,0.131,0.131,0.092,0.144	chr22:42523439-42523646,chr22:42523834-42523995,chr22:42524166-42524362,chr22:42524776-42524956,chr22:42526604-42526893	yes	CYP2D6,NDUFA6-AS1	CYP2D6	124030_[CYP2D6_(CONFIRMED)_DEBRISOQUINE_SENSITIVITY,608902|CODEINE_SENSITIVITY,608902]
chrX	10124975	10153226	GS140127_01	28252	2	3,3	3.60,3.05	0.026,0.013	chrX:10124975-10125150,chrX:10153052-10153226		CLCN4		302910_[CLCN4_(PROVISIONAL)_MENTAL_RETARDATION,X-LINKED_49/15,300114]
chrX	12719983	12720139	GS140127_01	157	1	3	4.18	0.033	chrX:12719983-12720139		FRMPD4		300838_[FRMPD4_(PROVISIONAL)_MENTAL_RETARDATION,X-LINKED_104,300983]
chrX	19369368	19371301	GS140127_01	1934	2	3,3	4.44,2.29	0.033,0.052	chrX:19369368-19369535,chrX:19371190-19371301		PDHA1	PDHA1	300502_[PDHA1_(CONFIRMED)_PYRUVATE_DEHYDROGENASE_E1-ALPHA_DEFICIENCY,312170]
chrX	24075740	24078309	GS140127_01	2570	2	3,3	3.89,2.57	0.013,0.033	chrX:24075740-24075881,chrX:24078195-24078309		EIF2S3		300161_[EIF2S3_(PROVISIONAL)_MENTAL_RETARDATION,X-LINKED,SYNDROMIC,BORCK_TYPE,300987]
chrX	44894166	44894240	GS140127_01	75	1	3	3.76	0.033	chrX:44894166-44894240		KDM6A	KDM6A	300128_[KDM6A_(PROVISIONAL)_KABUKI_SYNDROME_2,300867]
chrX	47040604	47041055	GS140127_01	452	2	1,1	-2.64,-3.92	0.026,0.020	chrX:47040604-47040810,chrX:47040896-47041055		RBM10		300080_[RBM10_(PROVISIONAL)_TARP_SYNDROME,311900]
chrX	49086672	49087081	GS140127_01	410	2	3,3	3.74,2.63	0.013,0.026	chrX:49086672-49086844,chrX:49086919-49087081		CACNA1F		300110_[CACNA1F_(CONFIRMED)_NIGHT_BLINDNESS,CONGENITAL_STATIONARY_(INCOMPLETE),2A,X-LINKED,300071|CONE-ROD_DYSTROPHY,X-LINKED,3,300476|ALAND_ISLAND_EYE_DISEASE,300600]
chrX	53250011	53250108	GS140127_01	98	1	3	4.35	0.118	chrX:53250011-53250108		KDM5C	KDM5C	314690_[KDM5C_(CONFIRMED)_MENTAL_RETARDATION,X-LINKED,SYNDROMIC,CLAES-JENSEN_TYPE,300534]
chrX	53613440	53613541	GS140127_01	102	1	3	3.77	0.026	chrX:53613440-53613541		HUWE1	HUWE1	300697_[HUWE1_(PROVISIONAL)_MENTAL_RETARDATION,X-LINKED_SYNDROMIC,TURNER_TYPE,300706]
chrX	54497006	54497203	GS140127_01	198	1	1	-3.58	0.026	chrX:54497006-54497203		FGD1	FGD1	300546_[FGD1_(CONFIRMED)_AARSKOG-SCOTT_SYNDROME,305400|MENTAL_RETARDATION,X-LINKED_SYNDROMIC_16,305400]
chrX	67417018	67417116	GS140127_01	99	1	3	5.38	0.033	chrX:67417018-67417116		OPHN1	OPHN1	300127_[OPHN1_(PROVISIONAL)_MENTAL_RETARDATION,X-LINKED,WITH_CEREBELLAR_HYPOPLASIA_AND_DISTINCTIVE_FACIAL_APPEARANCE,300486]
chrX	70360475	70361824	GS140127_01	1350	3	1,1,1	-2.39,-4.75,-3.25	0.033,0.033,0.020	chrX:70360475-70360717,chrX:70361070-70361230,chrX:70361723-70361824		MED12		300188_[MED12_(CONFIRMED)_OPITZ-KAVEGGIA_SYNDROME,305450|LUJAN-FRYNS_SYNDROME,309520|OHDO_SYNDROME,X-LINKED,300895]
chrX	77166184	77227268	GS140127_01	61085	2	3,3	4.97,2.85	0.039,0.039	chrX:77166184-77166342,chrX:77227108-77227268		ATP7A	ATP7A	300011_[ATP7A_(CONFIRMED)_MENKES_DISEASE,309400|OCCIPITAL_HORN_SYNDROME,304150|SPINAL_MUSCULAR_ATROPHY,DISTAL,X-LINKED_3,300489]
chrX	99661439	99665281	GS140127_01	3843	1	1	-3.99	0.007	chrX:99661439-99665281		PCDH19	PCDH19	300460_[PCDH19_(CONFIRMED)_EPILEPTIC_ENCEPHALOPATHY,EARLY_INFANTILE,9,300088]
chrX	128947643	128947711	GS140127_01	69	1	3	6.01	0.007	chrX:128947643-128947711		ZDHHC9	ZDHHC9	300646_[ZDHHC9_(CONFIRMED)_MENTAL_RETARDATION,X-LINKED_SYNDROMIC,RAYMOND_TYPE,300799]
chrX	133632410	133632476	GS140127_01	67	1	3	4.57	0.020	chrX:133632410-133632476		HPRT1	HPRT1	308000_[HPRT1_(CONFIRMED)_LESCH-NYHAN_SYNDROME,300322|HPRT-RELATED_GOUT,300323]
chrX	135758773	135758886	GS140127_01	114	1	3	4.54	0.020	chrX:135758773-135758886		ARHGEF6	ARHGEF6	300267_[ARHGEF6_(CONFIRMED)_MENTAL_RETARDATION,X-LINKED_46,300436]
chrX	135827372	135829761	GS140127_01	2390	2	3,4	2.97,8.82	0.039,0.033	chrX:135827372-135827516,chrX:135829657-135829761		ARHGEF6	ARHGEF6	300267_[ARHGEF6_(CONFIRMED)_MENTAL_RETARDATION,X-LINKED_46,300436]
chrX	139585142	139587235	GS140127_01	2094	1	1	-3.63	0.007	chrX:139585142-139587235		SOX3	SOX3	313430_[SOX3_(CONFIRMED)_MENTAL_RETARDATION,X-LINKED,WITH_ISOLATED_GROWTH_HORMONE_DEFICIENCY,300123|PANHYPOPITUITARISM,X-LINKED,312000]
